NeurAxis is a medical technology firm that has an FDA-approved treatment for abdominal pain in adolescents between 11 and 18 years of age. The company tweaked its terms of its initial IPO on Friday. The company filed a statement with the Securities and Exchange Commission stating that it will now offer 1.7 millions shares at $6 per share, and selling shareholders will offer an additional 2.8 million. The company had originally planned to sell 937,500 $8 shares, while selling shareholders would offer 1.8 millions shares. Alexander Capital L.P., the sole underwriter of the deal, has filed to list the company on the New York Stock Exchange with the ticker “NRXS”. The proceeds will be used to fund R&D, marketing and sales, executive officer contracts, debt repayment, and general corporate needs. The company’s net loss for the three months ending March was $2.2 million, a larger loss than the $500,000 loss recorded the previous year. As of March 31st 2023, our accumulated deficit was $36.1 million. In their audit opinion, our auditors expressed substantial doubts about our ability as a continuing concern. This is what the company states in its filing documents. The Renaissance IPO ETF IPO -2.81%, has gained 41% this year, while the S&P500 SPX -0.68%, has gained 18%.